Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan M Brotchie

Showing results (21-30 of 127) with videos related to

Pageof 13
Sort By:
Progress in Brain Research|September 6, 2008
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapySusan H Fox, Rosalind Chuang, Jonathan M Brotchie
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|December 6, 2003
Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptakeTimothy M Brown, Jonathan M Brotchie, Stephen M Fitzjohn
Movement Disorders : Official Journal of the Movement Disorder Society|December 11, 2012
Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trialsLorraine V Kalia, Jonathan M Brotchie, Susan H Fox
Experimental Neurology|July 4, 2006
Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted ratsNaomi P Visanji, Mark J Millan, Jonathan M Brotchie
Expert Opinion on Drug Delivery|November 22, 2005
Advances in the delivery of treatments for Parkinson's diseaseTom H Johnston, Susan H Fox, Jonathan M Brotchie
Nature Reviews. Neuroscience|July 28, 2017
Animal models of α-synucleinopathy for Parkinson disease drug developmentJames B Koprich, Lorraine V Kalia, Jonathan M Brotchie
The Lancet. Neurology|October 14, 2008
Non-dopaminergic treatments in development for Parkinson's diseaseSusan H Fox, Jonathan M Brotchie, Anthony E Lang
Movement Disorders : Official Journal of the Movement Disorder Society|July 29, 2006
Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failureSusan H Fox, Anthony E Lang, Jonathan M Brotchie
Experimental Neurology|December 31, 2003
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesiaPaula Ravenscroft, Sylvie Chalon, Jonathan M Brotchie, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 23, 2003
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's diseaseGregorio Segovia, Francisco Mora, Alan R Crossman, et al.
Pageof 13

Showing results (21-30 of 127) with videos related to

Sort By:
Pageof 13
Progress in Brain Research|September 6, 2008
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapySusan H Fox, Rosalind Chuang, Jonathan M Brotchie
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|December 6, 2003
Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptakeTimothy M Brown, Jonathan M Brotchie, Stephen M Fitzjohn
Movement Disorders : Official Journal of the Movement Disorder Society|December 11, 2012
Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trialsLorraine V Kalia, Jonathan M Brotchie, Susan H Fox
Experimental Neurology|July 4, 2006
Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted ratsNaomi P Visanji, Mark J Millan, Jonathan M Brotchie
Expert Opinion on Drug Delivery|November 22, 2005
Advances in the delivery of treatments for Parkinson's diseaseTom H Johnston, Susan H Fox, Jonathan M Brotchie
Nature Reviews. Neuroscience|July 28, 2017
Animal models of α-synucleinopathy for Parkinson disease drug developmentJames B Koprich, Lorraine V Kalia, Jonathan M Brotchie
The Lancet. Neurology|October 14, 2008
Non-dopaminergic treatments in development for Parkinson's diseaseSusan H Fox, Jonathan M Brotchie, Anthony E Lang
Movement Disorders : Official Journal of the Movement Disorder Society|July 29, 2006
Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failureSusan H Fox, Anthony E Lang, Jonathan M Brotchie
Experimental Neurology|December 31, 2003
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesiaPaula Ravenscroft, Sylvie Chalon, Jonathan M Brotchie, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 23, 2003
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's diseaseGregorio Segovia, Francisco Mora, Alan R Crossman, et al.
Pageof 13